Docoh
Loading...

AGTC Applied Genetic Technologies

Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Company profile

Ticker
AGTC
Exchange
Website
CEO
Susan Washer
Employees
Incorporated
Location
Fiscal year end
SEC CIK

AGTC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
18 May 21
30 Jun 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 89.53M 89.53M 89.53M 89.53M 89.53M 89.53M
Cash burn (monthly) (positive/no burn) (positive/no burn) 4.83M 4.94M 3.81M 4.29M
Cash used (since last report) n/a n/a 7.67M 7.84M 6.05M 6.81M
Cash remaining n/a n/a 81.87M 81.69M 83.48M 82.72M
Runway (months of cash) n/a n/a 17.0 16.5 21.9 19.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Dec 20 Koenig Scott Stock Option Common Stock Grant Aquire A No No 4.72 12,000 56.64K 12,000
16 Dec 20 Aliski William Stock Option Common Stock Grant Aquire A No No 4.72 12,000 56.64K 12,000
16 Dec 20 Hurwitz Edward Stock Option Common Stock Grant Aquire A No No 4.72 12,000 56.64K 12,000
16 Dec 20 Magovcevic Ivana Stock Option Common Stock Grant Aquire A No No 4.72 12,000 56.64K 12,000
16 Dec 20 James Rosen Stock Option Common Stock Grant Aquire A No No 4.72 12,000 56.64K 12,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

40.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 72 72
Opened positions 11 13 -15.4%
Closed positions 11 9 +22.2%
Increased positions 22 17 +29.4%
Reduced positions 19 25 -24.0%
13F shares
Current Prev Q Change
Total value 91.23M 100.84M -9.5%
Total shares 17.36M 15.17M +14.4%
Total puts 15.3K 23.6K -35.2%
Total calls 243.7K 284.8K -14.4%
Total put/call ratio 0.1 0.1 -24.2%
Largest owners
Shares Value Change
BLK Blackrock 1.73M $7.08M +7.1%
Interwest Partners Viii 1.4M $5.74M NEW
Interwest Venture Management 1.4M $5.74M -3.5%
Portolan Capital Management 1.31M $5.35M +0.5%
Intersouth Partners Vi 1.21M $4.97M NEW
Renaissance Technologies 1.02M $4.16M -4.9%
Vanguard 971.28K $3.97M +3.3%
Dimensional Fund Advisors 943.38K $3.86M -0.3%
DAFNA Capital Management 903.43K $3.7M -17.5%
Millennium Management 717.36K $2.93M +16.4%
Largest transactions
Shares Bought/sold Change
Interwest Partners Viii 1.4M +1.4M NEW
Intersouth Partners Vi 1.21M +1.21M NEW
Sofinnova Investments 0 -825.07K EXIT
Integrated Core Strategies 717.36K +717.36K NEW
Assenagon Asset Management 220.05K -224.88K -50.5%
DAFNA Capital Management 903.43K -191.71K -17.5%
683 Capital Management 175K -189.3K -52.0%
Pura Vida Investments 0 -176.41K EXIT
Colony 116.59K +116.59K NEW
BLK Blackrock 1.73M +114.22K +7.1%

Financial report summary

?
Management Discussion
  • The table below summarizes our research and development expenses by product candidate or program for the periods indicated.
  • External research and development expenses consist of collaboration, licensing, manufacturing, testing and other miscellaneous costs that are directly attributable to our most advanced product candidates and discovery programs. We do not allocate employee-related
  • costs, including share-based compensation, costs associated with broad technology platform improvements or other indirect costs, to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as internal research and development expenses in the table above.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abovementioned, Academy, Adelphi, adjacent, advisory, aforementioned, American, appointed, April, Bayer, BCVA, Cantor, care, cGMP, chain, COBRA, commence, commencement, commencing, construction, core, Corrected, coverage, customary, demonstrate, detachable, Director, discretionary, Distinguishing, dividend, double, durability, eligible, enable, extension, eye, fabrication, family, firm, fit, Fitzgerald, foot, footage, freestanding, Gartner, gave, genomic, Gerald, healthcare, homebuilder, hospital, Index, inflammation, inflammatory, instate, Island, joining, landlord, launch, lifestyle, luxury, medical, medicine, mutual, nonexclusive, ocular, OfferingSM, ophthalmic, owner, Park, people, President, prorated, recruit, redundancy, resigning, response, responsible, return, SAS, serve, served, shell, shown, single, southeastern, SparingVision, staffing, statistically, story, strategy, strict, Sullivan, supply, Susan, taxation, tenant, Terrace, Treasurer, twenty, uncollected, unexercised, unvested, Vice, Washer, WCI, William
Removed: adrenoleukodystrophy, ALD, dosing, estimation, placement, relate, revise